Sector • Healthcare Industry • Biotechnology & Pharmaceuticals |
Industry • Biotechnology & Pharmaceuticals |
Sector • Healthcare |
News
AIM ImmunoTech Advances Clinical Development Program for Advanced Recurrent Ovarian Cancer
Unveiling AIM ImmunoTech*s CEO Corner: Illuminating the Path to Revolutionary Therapies
AIM ImmunoTech*s Promising Clinical Pipeline Progress and Revenue Analysis
The Synergistic Impetus: Unleashing Ampligen and Imfinzi for Pancreatic Cancer Treatment
Promising Phase 2 Results: Ampligen Reduces Fatigue in Post-COVID Conditions
AIM ImmunoTech*s Ampligen Shows Potential in Promising Breast Cancer Study
AIM ImmunoTech Teams Up with Azenova to Accelerate Breakthrough Cancer Treatment Development
Very noticeable Deterioration in Revenues at the company during the third quarter of 2022